Every material Form 8-K Ardent Health, Inc. has filed with the SEC since September 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ardent Health reported third-quarter 2026 total revenue of $1.62 billion, up 3.1% from a year earlier, and net income attributable to the company of $45 million, compared with a net loss of $23 million in the same quarter of 2025. The company raised the low end of its full-year 2026 adjusted EBITDA guidance to $500 million from $485 million, keeping the top of the range at $535 million, and kept its revenue outlook unchanged.
Total revenue rose 3.1% year over year to $1.62 billion; adjusted admissions grew 2.9%.
Net income attributable to Ardent Health was $45 million, or $0.31 per diluted share, versus a net loss of $23 million, or $0.17 per share, a year earlier.
2026 adjusted EBITDA guidance is now $500 million to $535 million, up from $485 million to $535 million; revenue guidance stays at $6.4 billion to $6.7 billion.
The company ended the quarter with $766 million in cash and increased its share repurchase program by $25 million, with about $48 million remaining.
Ardent Health said its Board found on October 19, 2026 that former CEO Martin J. Bonick failed to fully disclose third-party compensation, and recharacterized his June 2026 separation as a termination for Cause. The company will stop about $4.5 million of unpaid severance and cancel his unvested performance-based restricted stock units, and it reserved its rights to pursue other remedies. The filing says no financial statements or previously disclosed results need revision.
Bonick's employment as President and CEO and his board service ended effective June 2, 2026.
On October 19, 2026, the Board determined that facts discovered after the separation date would have supported a termination for Cause.
Ardent will discontinue about $4.5 million of unpaid cash severance and cancel or forfeit outstanding unvested PRSUs.
The company says none of its financial statements or previously disclosed results need to be revised or corrected.
Ardent Health is revising its non-GAAP Adjusted EBITDA and Adjusted EBITDAR for 2025, removing $97.7 million of adjustments tied to two third-quarter 2025 items, following discussions with the SEC staff. The company says GAAP results, net income, cash flows, and 2026 results are unaffected, but the lower adjusted figures change how the company's 2025 performance measures are presented to investors.
Adjusted EBITDA for 2025 decreased from $545.0 million to $447.3 million
Adjusted EBITDAR for 2025 decreased from $709.3 million to $611.6 million
The $97.7 million removed relates to an accounts receivable collectability estimate change and a New Mexico professional liability accrual, both limited to Q3 2025
GAAP results, net income, and 2026 Adjusted EBITDA and EBITDAR are stated as unchanged
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ardent Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →